Literature DB >> 18391488

Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects.

Leena Aho1, Laura Parkkinen, Tuula Pirttila, Irina Alafuzoff.   

Abstract

BACKGROUND/AIMS: Abnormal processing of hyperphosphorylated tau (HPtau), amyloid-beta (Abeta) and alpha-synuclein (alphaS) proteins is considered as causative with regard to the clinical symptoms in age-related neurodegenerative diseases.
METHODS: In this retrospective, postmortem study applying immunohistochemical methodology, we assessed Alzheimer's-disease (AD)-related HPtau and Abeta pathology in 178 subjects with alphaS pathology.
RESULTS: These pathologies were frequently seen concomitantly, i.e. HPtau in 83% and Abeta in 62% of the alphaS-positive cases. Furthermore, the striatum was frequently involved, particularly in subjects with cognitive impairment (65%). The predictive value of widespread HPtau pathology, i.e. stages V-VI, with respect to cognitive impairment was high, since all 18 subjects presenting with this stage were demented. In contrast, the predictive value of widespread alphaS pathology, i.e. stages 5-6 according to Braak's Parkinson disease staging, was debatable. Fifty-three percent of the subjects with widespread alphaS pathology and no or mild AD-related HPtau pathology were cognitively unimpaired. It is noteworthy that striatal Abeta pathology was more often seen in demented subjects independently of HPtau and/or alphaS status.
CONCLUSION: The causative pathology in subjects with clinically diagnosed dementia with Lewy bodies needs to be clarified in future studies. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391488     DOI: 10.1159/000122963

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  7 in total

Review 1.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

Review 2.  Is Braak staging valid for all types of Parkinson's disease?

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2018-06-25       Impact factor: 3.575

3.  Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease.

Authors:  Kiren Ubhi; Kevin Peng; Stephanie Lessig; Jennilyn Estrella; Anthony Adame; Douglas Galasko; David P Salmon; Lawrence A Hansen; Claudia H Kawas; Eliezer Masliah
Journal:  Neurosci Lett       Date:  2010-09-21       Impact factor: 3.046

Review 4.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

Review 5.  Formation and development of Lewy pathology: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

6.  Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium.

Authors:  Irina Alafuzoff; Dietmar R Thal; Thomas Arzberger; Nenad Bogdanovic; Safa Al-Sarraj; Istvan Bodi; Susan Boluda; Orso Bugiani; Charles Duyckaerts; Ellen Gelpi; Stephen Gentleman; Giorgio Giaccone; Manuel Graeber; Tibor Hortobagyi; Romana Höftberger; Paul Ince; James W Ironside; Nikolaos Kavantzas; Andrew King; Penelope Korkolopoulou; Gábor G Kovács; David Meyronet; Camelia Monoranu; Tatjana Nilsson; Piero Parchi; Efstratios Patsouris; Maria Pikkarainen; Tamas Revesz; Annemieke Rozemuller; Danielle Seilhean; Walter Schulz-Schaeffer; Nathalie Streichenberger; Stephen B Wharton; Hans Kretzschmar
Journal:  Acta Neuropathol       Date:  2009-02-01       Impact factor: 17.088

7.  Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice.

Authors:  Lilia Zurkovsky; Evgeny Bychkov; Elviche L Tsakem; Carley Siedlecki; Randy D Blakely; Eugenia V Gurevich
Journal:  Dis Model Mech       Date:  2012-08-03       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.